Phenotypic diversity of genetic Creutzfeldt–Jakob disease: a histo-molecular-based classification

• DOI: 10.1007/s00401-021-02350-y
• Publication Date: 2021-07-29T08:02:52Z
• Authors: Simone Baiardi; Marcello Rossi; Angela Mammana; Brian S. Appleby; Marcelo A. Barria; Ignazio Calì; Pierluigi Gambetti; Ellen Gelpi; Armin Giese; Bernardino Ghetti; Jochen Herms; Anna Ladogana; Jacqueline Mikol; Suvankar Pal; Diane L. Ritchie; Viktoria Ruf; Otto Windl; Sabina Capellari; Piero Parchi
• Keywords: Adult; Male; Genotype; PrPSc Proteins; Creutzfeldt-Jakob disease (CJD); Insomnia, Fatal Familial; CJD subtypes; Fatal familial insomnia; FFI; Prion disease; Prion protein; Prion strains; PRNP; Creutzfeldt-Jakob Syndrome; Prion Proteins; Cohort Studies; 03 medical and health sciences; 0302 clinical medicine; Humans; Prion protein gene (PRNP); Codon; Aged; Original Paper; Prion strains; Middle Aged; 3. Good health; Phenotype; Mutation; CJD subtypes; Fatal familial insomnia; Female

AbstractThe current classification of sporadic Creutzfeldt–Jakob disease (sCJD) includes six major clinicopathological subtypes defined by the physicochemical properties of the protease-resistant core of the pathologic prion protein (PrPSc), defining two major PrPSc types (i.e., 1 and 2), and the methionine (M)/valine (V) polymorphic codon 129 of the prion protein gene (PRNP). How these sCJD subtypes relate to the well-documented phenotypic heterogeneity of genetic CJD (gCJD) is not fully understood. We analyzed molecular and phenotypic features in 208 individuals affected by gCJD, carrying 17 different mutations, and compared them with those of a large series of sCJD cases. We identified six major groups of gCJD based on the combination PrPSc type and codon 129 genotype on PRNP mutated allele, each showing distinctive histopathological characteristics, irrespectively of the PRNP associated mutation. Five gCJD groups, named M1, M2C, M2T, V1, and V2, largely reproduced those previously described in sCJD subtypes. The sixth group shared phenotypic traits with the V2 group and was only detected in patients carrying the E200K-129M haplotype in association with a PrPSc type of intermediate size (“i”) between type 1 and type 2. Additional mutation-specific effects involved the pattern of PrP deposition (e.g., a “thickened” synaptic pattern in E200K carriers, cerebellar “stripe-like linear granular deposits” in those with insertion mutations, and intraneuronal globular dots in E200K-V2 or -M”i”). A few isolated cases linked to rare PRNP haplotypes (e.g., T183A-129M), showed atypical phenotypic features, which prevented their classification into the six major groups. The phenotypic variability of gCJD is mostly consistent with that previously found in sCJD. As in sCJD, the codon 129 genotype and physicochemical properties of PrPSc significantly correlated with the phenotypic variability of gCJD. The most common mutations linked to CJD appear to have a variable and overall less significant effect on the disease phenotype, but they significantly influence disease susceptibility often in a strain-specific manner. The criteria currently used for sCJD subtypes can be expanded and adapted to gCJD to provide an updated classification of the disease with a molecular basis.